These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 177242

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia.
    Krut LH, Seftel HC, Joffe BI.
    S Afr Med J; 1977 Mar 12; 51(11):348-52. PubMed ID: 323994
    [Abstract] [Full Text] [Related]

  • 5. The metabolic spectrum of halofenate.
    Ryan JR.
    Int J Clin Pharmacol Biopharm; 1975 Jul 12; 12(1-2):239-43. PubMed ID: 51838
    [Abstract] [Full Text] [Related]

  • 6. [Treatment of hyperlipemia and hyperuricemia with 2-acetamidoethyl-(4-chlorophenyl)-(3-trifluoromethylphenoxy)-acetate (halofenate), a derivative of clofibrate].
    Keller C, Wolfram G, Zöllner N.
    Arzneimittelforschung; 1976 Jul 12; 26(12):2221-4. PubMed ID: 798591
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the effects of halofenate (MK-185) and clofibrate on plasma lipid and uric acid concentration in hyperlipoproteinemic patients.
    Lisch HJ, Patsch J, Sailer S, Braunsteiner H.
    Atherosclerosis; 1975 Jul 12; 21(3):391-9. PubMed ID: 1148032
    [Abstract] [Full Text] [Related]

  • 8. Halofenate in the treatment of type II hyperlipoproteinemia. Double blind comparison with clofibrate.
    Rees ED, Hamilton RD, Kanner IF, Wasson S, Hearn T.
    Atherosclerosis; 1976 Sep 12; 24(3):537-46. PubMed ID: 788722
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of halofenate and probenecid on serum lipids and uric acid in hyperlipidemic, hyperuricemic adults.
    Bassett DR, Mikkelsen WM, Buckingham RB, Block WD, Sidiq M, Shakibai A, DiGaetano R, Liou LL.
    Clin Pharmacol Ther; 1977 Sep 12; 22(3):340-51. PubMed ID: 330079
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and interactions of oxandrolone, halo-fenate and clofibrate in a factorial study on experimental acute nephrotic hyperlipidemia.
    Schapel GJ, Edwards KD.
    J Pharmacol Exp Ther; 1975 Jul 12; 194(1):274-84. PubMed ID: 1171221
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Triglyceride-lowering effect of chenodeoxycholic acid in patients with endogenous hypertriglyceridaemia.
    Miller NE, Nestel PJ.
    Lancet; 1974 Oct 19; 2(7886):929-31. PubMed ID: 4138590
    [No Abstract] [Full Text] [Related]

  • 19. Clofibrate in type II hyperlipoproteinemia.
    Ditzel J, Bang HO.
    Acta Med Scand; 1976 Oct 19; 200(1-2):55-58. PubMed ID: 183462
    [Abstract] [Full Text] [Related]

  • 20. Effect of halofenate on serum uric acid.
    Aronow WS, Harding PR, Khursheed M, Vangrow JS, Papageorge's NP.
    Clin Pharmacol Ther; 1973 Oct 19; 14(3):371-3. PubMed ID: 4572799
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.